Company Overview and News

0
Almaden Achieves 39% Gold And 47% Silver Mill Feed Grade Increase From Bulk Ore Sort Tests for Ixtaca

2018-07-16 globenewswire
VANCOUVER, British Columbia, July 16, 2018 (GLOBE NEWSWIRE) -- Almaden Minerals Ltd. (“Almaden” or “the Company”) (TSX:AMM) (NYSE American:AAU) is pleased to announce that it has achieved positive results from ore sorting trials carried out on ore samples from the Ixtaca gold-silver project located in Puebla State, Mexico. The ore sorting tests were carried out on a commercial XRT sorter using a bulk sample from the limestone host rock in the Ixtaca Main zone.
AMZ AAU AMM AXDDF

3
[Opinion] Rick Rule on Investing in Natural Resources

2018-07-09 oilvoice
Rick Rule, CEO of Sprott U.S. Holdings, speaks with Maurice Jackson of Proven and Probable about investing in precious and base metals, energy, agriculture and water.
MRZLF AMZ RIO RIO NSRPF IVN JROOF RVSDF EMX RTPPF UEC MOLOF RTNTF MAI JCO NEVDF AXDDF WPM MLRKF SPOXF RRI FCUUF MRO NVO IVPAF ATUSF RIO NCU PPT.U MRZ VGMTD FCU

5
Almaden Announces Results of Annual General Meeting

2018-06-28 globenewswire
VANCOUVER, British Columbia, June 28, 2018 (GLOBE NEWSWIRE) -- Almaden Minerals Ltd. (“Almaden" or the "Company") (TSX:AMM) (NYSE American:AAU) is pleased to provide the results of its Annual General Meeting held on June 28, 2018.
AMZ AAU AMM AXDDF

1
AXDDF / ALMADEX MINERALS LTD. / GLOBAL STRATEGIC MANAGEMENT INC - NO LONGER BENEFICIAL OWNER OF AZUCAR MINERALS (Passive Investment)

2018-06-08 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Amendment No. 1 Azucar Minerals Ltd. ----------------------------------------------------------------------------- (Name of Issuer)
AXDDF

1
AXDDF / ALMADEX MINERALS LTD. / GLOBAL STRATEGIC MANAGEMENT INC - NO LONGER BENEFICIAL OWNER OF AZUCAR MINERALS (Passive Investment)

2018-06-08 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Amendment No. 1 Azucar Minerals Ltd. ----------------------------------------------------------------------------- (Name of Issuer)
AXDDF

5
Almaden Closes Oversubscribed $9.4 Million Non-Brokered Private Placement

2018-06-07 globenewswire
VANCOUVER, British Columbia, June 07, 2018 (GLOBE NEWSWIRE) -- Almaden Minerals Ltd. (“Almaden” or “the Company”) (TSX:AMM) (NYSE American:AAU) is pleased to announce that it has closed its previously announced non-brokered private placement with the issuance of 9,440,000 units (“Units”) at $1.00 per Unit (the “Offering”). Each Unit consisted of one common share of the Company (a “Common Share”) and one-half of one non-transferable Common Share purchase warrant (each such whole Common Share purchase warrant, a “Warrant”).
AMZ AAU AMM AXDDF

3
Almadex Minerals Ltd. and Azucar Minerals Ltd. Announce Closing of Arrangement

2018-05-18 globenewswire
VANCOUVER, British Columbia, May 18, 2018 (GLOBE NEWSWIRE) -- Almadex Minerals Limited (“Old Almadex”) is pleased to announce that it has closed the previously announced statutory plan of arrangement (the “Plan of Arrangement”) under Section 288 of the Business Corporations Act (British Columbia) to spin-out Old Almadex’s early stage exploration projects, royalty interests, and certain other assets into Almadex Minerals Ltd.
AMZ NCMGF NCM NCMGY AXDDF

6
Almaden Announces $7 Million Non-Brokered Private Placement

2018-05-11 globenewswire
VANCOUVER, B.C., May 11, 2018 (GLOBE NEWSWIRE) -- Almaden Minerals Ltd. (“Almaden” or “the Company”) (TSX:AMM) (NYSE American:AAU) is pleased to announce a proposed non-brokered private placement financing (the "Offering") of up to 7,000,000 units (the “Units”) to raise up to $7,000,000 at a price of $1.00 per Unit.
AMZ AAU AMM AXDDF

6
Almadex Shareholders Approve Spinout Transaction; Almadex Updates Transaction Timing

2018-05-08 globenewswire
VANCOUVER, British Columbia, May 08, 2018 (GLOBE NEWSWIRE) -- Almadex Minerals Limited (“Almadex” or the “Company”); (TSX-V:AMZ); (OTCQX:AXDDF) is pleased to announce that shareholders at its Special Meeting of shareholders held today in Vancouver have voted 99.97% in favour of a special resolution approving a statutory plan of arrangement (the “Plan of Arrangement”) under Section 288 of the Business Corporations Act (British Columbia) to spin-out Almadex’s early stage exploration projects, royalty interests, and certain other assets into 1154229 B.
AMZ AAU AMM AXDDF

3
Abacus Announces Start of Drilling at Willow in Nevada

2018-04-24 globenewswire
VANCOUVER, British Columbia, April 24, 2018 (GLOBE NEWSWIRE) -- Abacus Mining & Exploration Corporation (“Abacus” or the “Company”) (TSXV:AME) is pleased to announce that a diamond drill is presently being mobilized to the Company’s Willow and adjacent Nev-Lorraine properties in the Yerington, Nevada copper camp.
AMZ AJAX QTA NCU QTRRF NEVDF AXDDF

5
Almadex Provides Update On Spin-Out Transaction and Newcrest Investment

2018-04-16 globenewswire
VANCOUVER, British Columbia, April 16, 2018 (GLOBE NEWSWIRE) -- Almadex Minerals Limited (“Almadex” or the “Company”) (TSX-V:AMZ) (OTCQX:AXDDF) announces that, further to its news release dated February 26, 2018, the Company has mailed and filed its Notice of Special Meeting of Shareholders (the “Meeting”) and the related Management Information Circular (the “Circular”) which describes, amongst other things, the proposed spin-out of Almadex’s early stage exploration projects, royalty interests and certain other assets, into a new public company (“Spinco”).
AMZ AAU AMM AXDDF

72
AXDDF / ALMADEX MINERALS LTD. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-04-11 fintel.io
ALMADEX MINERALS LTD. (OTC:AXDDF) has 3 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 3,955,959 shares. Largest shareholders include Global Strategic Management Inc, Tocqueville Asset Management L.p., and CHURCHILL MANAGEMENT Corp.
AMZ RCKT PETX ITEK ZYNE AXDDF

1
AXDDF / ALMADEX MINERALS LTD. / GLOBAL STRATEGIC MANAGEMENT INC - INITIAL BENEFICIAL OWNERSHIP FILING FOR ALMADEX MINERALS LTD (Passive Investment)

2018-04-11 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Almadex Minerals Ltd. ----------------------------------------------------------------------------- (Name of Issuer) Common Stock, no par value ---------
AXDDF

1
AXDDF / ALMADEX MINERALS LTD. / GLOBAL STRATEGIC MANAGEMENT INC - INITIAL BENEFICIAL OWNERSHIP FILING FOR ALMADEX MINERALS LTD (Passive Investment)

2018-04-11 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Almadex Minerals Ltd. ----------------------------------------------------------------------------- (Name of Issuer) Common Stock, no par value ---------
AXDDF

5
Almaden Files Form 20-F Documentation

2018-03-29 globenewswire
VANCOUVER, British Columbia, March 28, 2018 (GLOBE NEWSWIRE) -- Almaden Minerals Ltd. (“Almaden” or “the Company”) (TSX:AMM) (NYSE American:AAU) announces that its Form 20-F for the fiscal year ended December 31, 2017 has been filed with the U.S. Securities and Exchange Commission. The Form 20-F and the Company's audited consolidated financial statements for the years ended December 31, 2017 and 2016 are available on the Company's website at http://www.
AMZ AAU AMM AXDDF

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 020289104